2. Search Result
Search Result
Results for "

Integrin

" in MedChemExpress (MCE) Product Catalog:

170

Inhibitors & Agonists

6

Biochemical Assay Reagents

66

Peptides

17

Inhibitory Antibodies

12

Natural
Products

69

Recombinant Proteins

1

Isotope-Labeled Compounds

21

Antibodies

Cat. No. Product Name Target Research Area
  • HY-P2532
    Integrin Binding Peptide

    		Integrin Others
    Integrin Binding Peptide is derived by fibronectin. Integrin Binding Peptide can be used for PEG hydrogel preparation .
  • HY-P1868A
    α2β1 Integrin Ligand Peptide TFA
    2 Publications Verification

    DGEA peptide TFA

    		 Integrin Others
    α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
  • HY-P1654
    A20FMDV2

    		Integrin Cancer
    A20FMDV2 is a selective αvβ6 integrin inhibitor (IC50: 3 nM), with an activity 1,000-fold more selective for αvβ6 than for other RGD-directed integrins (αvβ3, αvβ5, and α5β1). A20FMDV2 can be derived from the foot-and-mouth disease virus. A20FMDV2 can be radiolabeled for the PET imaging of αvβ6 integrin-positive tumors .
  • HY-P0023
    Cyclo(-RGDfK)
    Maximum Cited Publications
    14 Publications Verification

    		 Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
  • HY-P0178A
    LXW7 TFA

    		Integrin Inflammation/Immunology
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
  • HY-P10045
    Integrin signaling inhibitor, mP13

    		Peptides Cardiovascular Disease
    Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .
  • HY-P6022
    G4RGDSP, integrin-binding peptide

    		Peptides Others
    G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology
  • HY-P3523
    KGDS

    		Integrin Others
    KGDS is synthetic peptides, targeting integrin GPIIb-IIIa located on the membrane of human activated platelets. Amino acid sequence: Lys-Gly-Asp-Ser .
  • HY-P1868
    α2β1 Integrin Ligand Peptide

    DGEA peptide

    		 Integrin Infection
    α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
  • HY-P0178
    LXW7

    		Integrin Inflammation/Immunology
    LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
  • HY-P0023A
    Cyclo(-RGDfK) TFA
    Maximum Cited Publications
    14 Publications Verification

    		 Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
  • HY-P0322
    GRGDSPK

    EMD 56574

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
  • HY-P0322A
    GRGDSPK TFA

    EMD 56574 TFA

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK TFA (EMD 56574 TFA) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK TFA is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK TFA is used to study the role of integrins in bone formation and resorption .
  • HY-P10417
    RTDLDSLRTYTL

    		Integrin Others Cancer
    RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .
  • HY-P3732
    RGD-4C

    		Integrin Cancer
    RGD-4C is a arginine-glycine-aspartic acid peptide (ACDCRGDCFC) with integrin binding activity. The Arg-Gly-Asp (RGD) sequence serves as the primary integrin recognition site in extracellular matrix proteins, and peptides containing this sequence can mimic the recognition specificity of the matrix proteins. RGD-4C is a αv-integrin ligand, can conjugate with bioactive molecule to exert antitumor effects in animal models .
  • HY-P4896
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro

    		Integrin Cancer
    FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .
  • HY-P3533
    EILEVPST

    		Integrin Cardiovascular Disease
    EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .
  • HY-P1613
    Cyclo(Arg-Gly-Asp-D-Phe-Val)

    Cyclo(RGDfV); C(RGDfV)

    		 Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
  • HY-P1613A
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

    Cyclo(RGDfV) TFA; C(RGDfV) TFA

    		 Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
  • HY-P3448
    Certepetide

    CEND-1; iRGD; LSTA1

    		 Integrin Complement System Cancer
    Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors .
  • HY-P0290A
    GRGDSP TFA
    5 Publications Verification

    		 Integrin Cancer
    GRGDSP (TFA) is an integrin inhibitor.
  • HY-P0290
    GRGDSP
    5 Publications Verification

    		 Integrin Cancer
    GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
  • HY-P3522
    REDV

    		Integrin Cancer
    REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion .
  • HY-P2267
    LDV
    1 Publications Verification

    		 Integrin Others
    LDV is a non-fluorescent analog of LDV-FITC. LDV is a α4β1 integrin (VLA-4) ligand, and binds α4β1 integrin in leukemia cells .
  • HY-P3522A
    REDV TFA

    		Integrin Cancer
    REDV TFA is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV TFA can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV TFA can be used for the research of cell adhesion .
  • HY-P5812
    IDR 1002

    		Integrin Inflammation/Immunology
    IDR-1002 is an anti-infective peptide that enhances the ability of human monocytes to migrate toward chemokines on fibronectin. IDR-1002 also induces adhesion and activation of β1-integrin, a mechanism that promotes monocyte recruitment .
  • HY-12290
    Arg-Gly-Asp-Ser
    5 Publications Verification

    RGDS peptide; Fibronectin tetrapeptide

    		 Integrin Inflammation/Immunology
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
  • HY-100563
    Cyclo(RGDyK) trifluoroacetate
    3 Publications Verification

    		 Integrin Cancer
    Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
  • HY-100563A
    Cyclo(RGDyK)
    3 Publications Verification

    		 Integrin Cancer
    Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.
  • HY-P1897
    Fibronectin Active Fragment Control

    		Peptides Inflammation/Immunology
    Fibronectin Active Fragment Control is an active peptide fragment of fibronectin. Fibronectin is a glycoprotein interacting with integrins .
  • HY-12290A
    Arg-Gly-Asp-Ser TFA

    RGDS peptide TFA; Fibronectin tetrapeptide TFA

    		 Integrin Inflammation/Immunology
    Arg-Gly-Asp-Ser (TFA) is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser (TFA) directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1 .
  • HY-P5038
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro)

    c(GRGDSP)

    		 Integrin Cancer
    Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide. Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) is a synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin expressed on Caco-2 cells .
  • HY-P0278
    RGD
    5+ Cited Publications

    		 Integrin Cancer
    RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
  • HY-P10038
    mP6

    Myr-FEEERA-OH

    		 Integrin Infection
    mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα13 with integrin β3 without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .
  • HY-P6351
    c(avb6)-DOTA TFA

    		Integrin Cancer
    c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DPTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic .
  • HY-P0278A
    RGD Trifluoroacetate
    5+ Cited Publications

    		 Integrin Cancer
    RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.
  • HY-P1188
    LDV-FITC

    		Integrin Cancer
    LDV-FITC, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC can be used to detect α4β1 integrin affinity .
  • HY-P0031
    Cyclo(RADfK)
    1 Publications Verification

    		 Integrin Others
    Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.
  • HY-P3530
    G-{d-Arg}-GDSP

    		Peptides Others
    G-{d-Arg}-GDSP is an RGD peptide analogue that binds to the adhesion receptor of integrins and inhibits cellular fibronectin attachment as well as osteoclast resorption .
  • HY-P1188A
    LDV-FITC TFA

    		Integrin Cancer
    LDV-FITC TFA, a fluorescent peptide, is a FITC-conjugated LDV peptide (HY-P2267). LDV-FITC TFA binds to the α4β1 integrin with high affinity (Kd: 0.3 nM and 12 nM for binding to U937 cells in the presence and absence of Mn 2+ respectively). LDV-FITC TFA can be used to detect α4β1 integrin affinity .
  • HY-P4903
    RGD-targeted Proapoptotic Peptide

    		Peptides Cancer
    RGD-targeted Proapoptotic Peptide is a peptide. The C-terminal RGD-4C peptide (ACDCRGDCFC) binds preferentially to integrins at sites of tumor angiogenesis.
  • HY-P5053
    Galacto-RGD

    		Integrin Cancer
    Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α₅β₃ selective tracer .
  • HY-P5929
    VnP-16

    		Integrin FAK Inflammation/Immunology
    VnP-16 can promote bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation .
  • HY-P5287
    cRGDfK-thioacetyl ester

    		Integrin Cancer
    cRGDfK-thioacetyl ester is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
  • HY-P1187
    HSDVHK-NH2

    		Integrin Cancer
    HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM) .
  • HY-P5287A
    cRGDfK-thioacetyl ester TFA

    		Integrin Cancer
    cRGDfK-thioacetyl ester TFA is a bioactive polypeptide molecule. cRGDfK peptide has a selective affinity for integrins. cRGDfK peptide can modify NIR fluorescent probes for cancer targeting imaging .
  • HY-P1187A
    HSDVHK-NH2 TFA

    		Integrin Cancer
    HSDVHK-NH2 TFA is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM) .
  • HY-125053A
    Batifiban TFA

    		Glycoprotein VI Cardiovascular Disease
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3 .
  • HY-P0122
    iRGD peptide
    5 Publications Verification

    c(CRGDKGPDC)

    		 Integrin Cancer
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
  • HY-P5098
    E(c(RGDfK))2

    		Peptides Cancer
    E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor targeting properties. Increased uptake of E(c(RGDfK)) in human ovarian cancer OVCAR-3 xenograft tumors may be useful in cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: